Ocular biomarkers for anemia in diabetic kidney disease include disruption of the external limiting membrane and ellipsoid zone.

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of chronic kidney disease in the US ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Cynata Therapeutics Limited ( OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and Managing Director ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- "Yo-yo" dieting -- repeatedly losing and gaining weight -- can significantly ...

A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI ...